The CX3C Chemokine Fractalkine (CX3CL1) Is Detectable in Serum of B Cell Chronic Lymphocytic Leukemia Patients with Lymph Node Involvement

Morabito, Fortunato; Merendino, Rosaria Alba; Penna, Giuseppa; Cuzzola, Mariella; Stelitano, Caterina; Callea, Vincenzo; Pasquale, Giuseppe Di; Pl, Minciullo; Gangemi, Sebastiano

doi:10.1159/000083456

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This chemokine remains unique, being a transmembrane protein able to directly and firmly bind its receptor. According to the study performed by Morabito et al [14], CX3CL1 levels correlated with LN involvement measured by computed tomography surveys, and the time to treatment was found to be shorter in patients with detectable serum levels. CX3CL1 could also be used as a predictor of disease progression, especially in earlier stages of disease (Table 2) [14].…”

Section: Cx3cl1 and Its Receptor Cx3cr1mentioning

confidence: 95%

“…According to the study performed by Morabito et al [14], CX3CL1 levels correlated with LN involvement measured by computed tomography surveys, and the time to treatment was found to be shorter in patients with detectable serum levels. CX3CL1 could also be used as a predictor of disease progression, especially in earlier stages of disease (Table 2) [14]. In addition, Ferrer et al correlated CX3CR1 on B-CLL cells with ZAP70 expression [68].…”

Section: Cx3cl1 and Its Receptor Cx3cr1mentioning

confidence: 95%

“…B-CLL cells possess a characteristic chemokine receptor profile; hence, receptor inhibition could function as a promising tool for treatment [13]. In addition, since the expression of some chemokines and chemokine receptors correlates with important and well-established predictive clinical parameters, they might be implemented as new diagnostic markers [14][15][16][17][18]. In the following, the different aspects of selected chemokine receptors and ligands and their involvement in B-CLL pathophysiology will be illustrated, including the support of homing, retention and survival in tissue microenvironments and the induction of resistance to spontaneous and chemotherapy-induced apoptosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact

2009

View full text Add to dashboard Cite

International audienceChemokines are centrally involved in leukocyte migration, homing and haematopoiesis. Besides these physiological aspects, their role in pathological processes especially with respect to solid tumour and haematological neoplasias is well established. In this context, the focus was set here on disclosing their contribution in B cell chronic lymphocytic leukaemia (B-CLL), which is regarded as the most characteristic low-grade lymphoma. Up to now, it has been demonstrated that several chemokines are involved in migration of B-CLL cells to lymph nodes, secondary lymphoid organs and bone marrow. Moreover, some chemokines are known to have an anti-apoptotic effect and thus contribute to the survival of B-CLL cells. By interfering with both of these aspects, new therapeutic targets for this yet incurable disease may be developed. Furthermore, a correlation can be drawn between the concentration of some chemokines in patients' serum, the expression of their respective receptors on B-CLL cells and well-established predictive clinical parameters. Consequently, further systematic investigation of the chemokine network may lead to the identification of new diagnostic and prognostic markers. This review focuses on the impact of chemokines and their receptors on B-CLL pathophysiology and points out potential implications for both treatment and diagnosis

show abstract

Section: Cx3cl1 and Its Receptor Cx3cr1mentioning

confidence: 95%

Section: Cx3cl1 and Its Receptor Cx3cr1mentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact

2009

View full text Add to dashboard Cite

show abstract

“…In this study, we found high serum levels ofFKN in all 11 patients with allergic rhinitis and/or asthma (512.45 ± 247.07 pg/ml) (Table I) Several studies have demonstrated the involvement of FKN in inflammatory conditions, such as in atherosclerosis, diabetes mellitus with atherosclerosis and transplant vascular disease (11), in glomerulonephritis (12), in inflammatory neurological diseases (13), in rheumatoid arthritis (14), in B-cell chronic lymphocytic leukemia with lymphnode involvement (15 The role of cytokines and chemokines in the pathogenesis of allergic diseases is becoming more and more evident; it may be important because the prevalence of asthma and allergic disease increases around the world, it is clear that more effective therapies and disease-modifying agents are needed. We have previously demonstrated, for example, that fluticasone propionate may efficiently diffuse to IL-8 producing cells during airway inflammatory events, and that IL-8 may represent a target for the pharmacological actions of fluticasone propionate in asthma (17)(18).…”

Section: Resultsmentioning

confidence: 51%

The CX3C-Chemokine Fractalkine (CX3CL1) is Detectable in Serum of Patients Affected by the Inflammatory Diseases Allergic Rhinitis and/or Asthma

Pl¹,

Patafi²,

Giannetto³

et al. 2005

Eur J Inflamm

Self Cite

View full text Add to dashboard Cite

Fractalkine (FKN) is a chemokine able to mediate the initial capture, firm adhesion, and activation of circulating leukocytes. Many tissues express FKN mRNA and FKN expression is increased during inflammatory conditions. To assess a possible involvement in allergic airway disease, we detected serum levels of FKN in a group of patients affected by allergic rhinitis and/or asthma and found high serum levels of FKN in all patients and in only 26% of healthy donors at lower concentrations. The present results underscore the potential role that this chemokine may play in the pathogenesis of respiratory allergic diseases.

show abstract

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia

Vitale

Boccellato

Comba

et al. 2021

Cancers

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is characterized by a wide spectrum of immune alterations, affecting both the innate and adaptive immunity. These immune dysfunctions strongly impact the immune surveillance, facilitate tumor progression and eventually affect the disease course. Quantitative and functional alterations involving conventional T cells, γδ T cells, regulatory T cells, NK and NKT cells, and myeloid cells, together with hypogammaglobulinemia, aberrations in the complement pathways and altered cytokine signature have been reported in patients with CLL. Some of these immune parameters have been shown to associate with other CLL-related characteristics with a known prognostic relevance or to correlate with disease prognosis. Also, in CLL, the complex immune response dysfunctions eventually translate in clinical manifestations, including autoimmune phenomena, increased risk of infections and second malignancies. These clinical issues are overall the most common complications that affect the course and management of CLL, and they also may impact overall disease prognosis.

show abstract

The CX3C Chemokine Fractalkine (CX3CL1) Is Detectable in Serum of B Cell Chronic Lymphocytic Leukemia Patients with Lymph Node Involvement

Cited by 3 publications

References 12 publications

The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact

The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact

The CX3C-Chemokine Fractalkine (CX3CL1) is Detectable in Serum of Patients Affected by the Inflammatory Diseases Allergic Rhinitis and/or Asthma

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia

Contact Info

Product

Resources

About